国际呼吸杂志
國際呼吸雜誌
국제호흡잡지
INTERNATIONAL JOURNAL OF RESPIRATION
2013年
21期
1639-1641
,共3页
张洪浩%钟声%甘兵%许柳丽%伍建光%邓改枝%张春梅%陈秋兰
張洪浩%鐘聲%甘兵%許柳麗%伍建光%鄧改枝%張春梅%陳鞦蘭
장홍호%종성%감병%허류려%오건광%산개지%장춘매%진추란
慢性阻塞性肺疾病%噻托溴铵%沙美特罗替卡松
慢性阻塞性肺疾病%噻託溴銨%沙美特囉替卡鬆
만성조새성폐질병%새탁추안%사미특라체잡송
Chronic obstructive pulmonary disease%Tiotropium Bromide%Salmeterol Fluticasone
目的 分析噻托溴铵(思力华)与沙美特罗替卡松(舒利迭)联合应用于中重度慢性阻塞性肺疾病(COPD)患者的临床效果.方法 选取2011年8月至2012年11月,我院相关科室所收治的中重度COPD患者110例为研究对象,并将其随机分成两组,对照组55例患者以沙美特罗替卡松单药治疗,实验组55例患者则以噻托溴铵与沙美特罗替卡松联合治疗.对两组患者的疗效进行对比分析.结果 经过3个月的治疗,两组患者呼吸困难的现象均有所改善,但实验组患者的效果明显更好,组间差异明显,P <0.05.此外,相比于对照组,实验组患者各项血气指标与肺部功能指标(除PaCO2)均明显升高,组间差异较大,P <0.05.结论 相比于沙美特罗替卡松单药治疗,噻托溴铵与沙美特罗替卡松联合治疗中重度COPD患者的疗效更佳,患者无论是血气、肺部功能,还是呼吸困难情况均得到明显的改善,且临床不良反应少,值得肯定,在临床治疗中应普及应用.
目的 分析噻託溴銨(思力華)與沙美特囉替卡鬆(舒利迭)聯閤應用于中重度慢性阻塞性肺疾病(COPD)患者的臨床效果.方法 選取2011年8月至2012年11月,我院相關科室所收治的中重度COPD患者110例為研究對象,併將其隨機分成兩組,對照組55例患者以沙美特囉替卡鬆單藥治療,實驗組55例患者則以噻託溴銨與沙美特囉替卡鬆聯閤治療.對兩組患者的療效進行對比分析.結果 經過3箇月的治療,兩組患者呼吸睏難的現象均有所改善,但實驗組患者的效果明顯更好,組間差異明顯,P <0.05.此外,相比于對照組,實驗組患者各項血氣指標與肺部功能指標(除PaCO2)均明顯升高,組間差異較大,P <0.05.結論 相比于沙美特囉替卡鬆單藥治療,噻託溴銨與沙美特囉替卡鬆聯閤治療中重度COPD患者的療效更佳,患者無論是血氣、肺部功能,還是呼吸睏難情況均得到明顯的改善,且臨床不良反應少,值得肯定,在臨床治療中應普及應用.
목적 분석새탁추안(사력화)여사미특라체잡송(서리질)연합응용우중중도만성조새성폐질병(COPD)환자적림상효과.방법 선취2011년8월지2012년11월,아원상관과실소수치적중중도COPD환자110례위연구대상,병장기수궤분성량조,대조조55례환자이사미특라체잡송단약치료,실험조55례환자칙이새탁추안여사미특라체잡송연합치료.대량조환자적료효진행대비분석.결과 경과3개월적치료,량조환자호흡곤난적현상균유소개선,단실험조환자적효과명현경호,조간차이명현,P <0.05.차외,상비우대조조,실험조환자각항혈기지표여폐부공능지표(제PaCO2)균명현승고,조간차이교대,P <0.05.결론 상비우사미특라체잡송단약치료,새탁추안여사미특라체잡송연합치료중중도COPD환자적료효경가,환자무론시혈기、폐부공능,환시호흡곤난정황균득도명현적개선,차림상불량반응소,치득긍정,재림상치료중응보급응용.
Objective To analyze the clinical effect of the combination of Spiriva (Tiotropium Bromide) and Seretide (Salmeterol Fluticasone) in treatment of moderate to-severe chronic obstructive pulmonary disease (COPD).Methods A total of 110 moderate-to-severe COPD patients in our hospital from August 2011 to November 2012 were selected as the subjects,who were randomized into two groups,with 55 patients of the control group treated by Seretide and 55 patients of the experimental group treated by the combination of Spiriva and Seretide.The curative effects of two groups were compared.Results After 3 months of treatment,dyspnea was relieved in both two groups,but patients of the experimental group had better effects,with significant difference shown among groups (P <0.05).In addition,indexes of blood gas and pulmonary function in patients of the experimental group were significantly improved compared with those of the control group,showing significant difference among groups (P <0.05).Conclusions Compared with Seretide monotherapy,combination Spiriva and Seretide has better curative effect in treatment of moderate-to-severe COPD.The blood gas,pulmonary function and dyspnea condition of patients can all be improved with less clinical side effects.Thus it is worthy of being widely used in clinical treatment.